BPC-157 and TB-500 blend (20 mg)
BPC-157 and TB-500 are the two peptides most often sold for injury recovery, and the most common blend puts 10 mg of each in one vial. It is also the only combination in the repair-blend family that anyone has given to animals or people as a pair, which makes it the best place to see how little that evidence amounts to. Sellers often call it 'Wolverine'; the name is a market nickname, not an ingredient list, and the same name can mean different contents.
As sold, one vial: BPC-157 10 mg, TB-500 10 mg. Statuses as of October 3, 2026. Reviewed by the Grey Peptides Editorial Board. Nothing here is a recommendation or a dose, and no seller is named or linked.
Each component at a glance
From our encyclopedia and FDA's July 2026 Pharmacy Compounding Advisory Committee record. Evidence grades follow the rubric on our methodology page.
| Component | Evidence | FDA status | PCAC, July 2026 | WADA 2026 | WADA 2027 | Interactions |
|---|---|---|---|---|---|---|
| BPC-157 | Low | Research Chemical | Recommended (8-6, July 23, 2026); FDA has not acted | Prohibited (S0) | Prohibited (S0) | Partly reviewed |
| TB-500 | Low | Research Chemical | Recommended (8-6, July 23, 2026); FDA has not acted | Prohibited (S2.3) | Prohibited (S2.3) | Partly reviewed |
What one vial contains: the ratio arithmetic
The vial holds 20 mg in total. Whatever volume of water is added and however much is drawn, every draw carries the components in the same proportions. The table expresses each as a share of the vial, as a multiple of the smallest component (BPC-157), and as a concentration if the whole vial were dissolved in 2 mL or 3 mL of water. These are arithmetic illustrations of what is in the vial, not suggested volumes or doses.
| Component | In the vial | Share | × BPC-157 | In 2 mL | In 3 mL |
|---|---|---|---|---|---|
| BPC-157 | 10 mg | 50.0% | 1 | 5 mg/mL | 3.33 mg/mL |
| TB-500 | 10 mg | 50.0% | 1 | 5 mg/mL | 3.33 mg/mL |
The Blend & Stack Calculator runs the same arithmetic for any volume and draw, with this composition as a preset (BPC-157 and TB-500, 20 mg (10/10)).
What the name means, and does not
The pair is widely marketed under a superhero nickname. Our Name Decoder records that the name usually means BPC-157 and TB-500 together, often 10 mg of each, but that sellers also use it for BPC-157 alone and for the four-peptide mix with GHK-Cu and KPV; a consumer health outlet described it as a combination of TB-500 and BPC-1571. The nickname therefore tells you very little about what is in a given vial. Read the milligrams on the label, and check that a certificate of analysis names and quantifies both peptides.
BPC-157 on its own
BPC-157 is a synthetic 15-amino-acid peptide derived from a protein in human gastric juice. Its reputation rests on decades of rodent work, largely from one research group in Zagreb, showing faster healing of gut, tendon, ligament, muscle and bone injuries2. A 2025 systematic review found preclinical support for healing in fractures, tendons, ligaments and muscle, while noting that use by clinicians and athletes has run far ahead of human evidence3.
That human evidence is two small reports. In a 2025 pilot, two adults who had used BPC-157 before received intravenous infusions without side effects or changes in heart, liver, kidney, thyroid or glucose markers; there was no control group4. A 2021 chart review of knee injections at one clinic reached 16 patients by phone, with no control group and recalled pain as the outcome5.
TB-500 on its own
TB-500 is a seven-amino-acid fragment of thymosin beta-4, a 43-residue protein involved in cell migration and repair. Almost everything published about 'TB-500' is really about the parent protein. Thymosin beta-4 has been tested in people: a randomised safety study of single and repeated intravenous doses in 40 healthy volunteers found adverse events infrequent6, a multicentre trial tested it as a topical treatment for venous leg ulcers7, and it reached phase 3 trials as eye drops for dry eye and nerve-related corneal disease8. None of that tested the fragment that is sold, injected under the skin.
Reviews of thymosin beta-4 also discuss its involvement in tumour biology alongside its role in repair, one reason caution is advised for anyone with a history of cancer9.
The only two reports of the pair
The rat study is the only controlled test of the two together. In 2026, researchers cut and repaired the Achilles tendon in 32 rats and gave BPC-157, TB-500, both, or nothing, injected into the abdomen daily for four weeks. Compared with untreated rats, only the TB-500 group showed a statistically significant gain in the load the tendon could bear before breaking. The combination group scored significantly better on one tissue-structure scale, and BPC-157 alone did not reach significance on the overall scores10. The doses were calculated per kilogram of body weight, and the peptides were not drawn from a fixed-ratio vial.
The human report is four patients in the 2021 knee chart review who received separate injections of BPC-157 and thymosin beta-4 (the parent protein, not TB-500); three of the four reported significant relief5. With no comparison group, a recalled outcome and four people, it shows that the combination has been used, not that it works.
Read together, the evidence does not show that adding BPC-157 to TB-500 improves on TB-500 alone, even in rats. It does not address people, safety, or what happens when the two are mixed and stored in one vial.
Equal parts: what the ratio means here
Because the vial holds equal milligrams of each peptide, every draw delivers equal milligrams of each, as the table above shows. That avoids the dominance problem of the larger blends, where GHK-Cu or TB-500 outweighs everything else, but it keeps the basic limits of any blend. The two cannot be adjusted separately; one cannot be stopped while the other continues; and if a reaction occurs there is no way to tell which peptide caused it. Equal milligrams also do not mean equal numbers of molecules, because the two peptides differ in size, and nobody has established what amount of either is appropriate in people.
Regulatory status in the United States
Neither peptide is approved by FDA. Both were among the six that FDA's Pharmacy Compounding Advisory Committee voted, in July 2026, to recommend for the list of substances pharmacies may use in compounding, each by 8 votes to 6 with one abstention, after FDA's reviewers had advised against them11. As of October 3, 2026, FDA had not acted on the votes, so neither can yet be lawfully compounded. If FDA does adopt them, compounding would cover a pharmacy preparing a substance for an individual patient's prescription, not a pre-mixed vial sold online for 'research'. FDA has sent warning letters to online sellers of peptides labelled for research use only12.
For tested athletes
Both are prohibited at all times under the World Anti-Doping Code: BPC-157 is named under S0, non-approved substances, and TB-500 under S2, peptide hormones, growth factors and related substances13. Anti-doping laboratories test for both, and an athlete is strictly liable for what is in their sample regardless of what a label said. The 2027 List keeps both statuses13.
What to check before anything else
Three questions apply to any vial sold as this pair. Are both peptides stated in milligrams, and does the certificate of analysis quantify both by name, with purity for each, from an identifiable laboratory and for the batch in hand? Is the product labelled 'for research use only', which signals it is not made or tested for people? And is the reason for using it something that a clinician has assessed? Our COA Decoder shows what a genuine report contains, our BPC-157 vs TB-500 comparison sets the two side by side, and our guide to taking them as a stack covers separate vials rather than a blend.
Sources
- Forbes Health. The FDA Eased Restrictions On Six Peptides: What Consumers Should Know (describing the combination of TB-500 and BPC-157 by its nickname). Cited in the Grey Peptides Name Decoder.
- Seiwerth, S., et al. (2018). BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing. Curr Pharm Des, 24. PubMed 29998800 ↗
- Vasireddi, N., et al. (2025). Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J, 21. PubMed 40756949 ↗
- Lee, E., et al. (2025). Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med, 31. PubMed 40131143 ↗
- Lee, E., et al. (2021). Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med, 27. PubMed 34324435 ↗
- Ruff, D., et al. (2010). A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Ann N Y Acad Sci, 1194. PubMed 20536472 ↗
- Guarnera, G., et al. (2007). Thymosin beta-4 and venous ulcers: clinical remarks on a European prospective, randomized study on safety, tolerability, and enhancement on healing. Ann N Y Acad Sci, 1112. PubMed 17495250 ↗
- Sosne, G. (2018). Thymosin beta 4 and the eye: the journey from bench to bedside. Expert Opin Biol Ther, 18. PubMed 30063853 ↗
- Bjørklund, G., et al. (2020). Thymosin β4: A Multi-Faceted Tissue Repair Stimulating Protein in Heart Injury. Curr Med Chem, 27. PubMed 31333080 ↗
- Biçer, O., et al. (2026). Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Jt Dis Relat Surg, 37. PubMed 42542926 ↗
- U.S. Food and Drug Administration. July 23-24, 2026 meeting of the Pharmacy Compounding Advisory Committee: votes on BPC-157 and TB-500 (8 yes, 6 no, 1 abstain each). Page current as of August 6, 2026; re-read October 3, 2026. Source ↗
- U.S. Food and Drug Administration. Warning letter 694608 to an online seller of peptides labelled for research use only, December 10, 2024. Source ↗
- World Anti-Doping Agency. The 2026 Prohibited List (S0; S2), in force January 1 to December 31, 2026; the 2027 List keeps the same statuses. Read in full July 16, 2026. Source ↗
Related: the blends and stacks hub, the Name Decoder, the COA Decoder and the Interaction Matrix. Last updated October 3, 2026.